Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma

Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma

Nivolumab, a programmed death-1 checkpoint inhibitor, is worldwide available for metastatic renal cell carcinoma (mRCC). Limited data exist on the response to vascular endothelial growth factor receptor-tyrosine kinase inhibitor (TKI) therapy after administration of nivolu­mab. In this case study, w...

Full description

Bibliographic Details
Main Authors: Tsukasa Narukawa, Fumiya Hongo, Atsuko Fujihara, Akihisa Ueno, Toru Matsugasumi, Osamu Ukimura
Format: Article
Language:English
Published: Karger Publishers 2020-03-01
Series:Case Reports in Oncology
Subjects:
tumor lysis syndrome
nivolumab
renal cell carcinoma
tyrosine kinase inhibitor
Online Access:https://www.karger.com/Article/FullText/506196

Internet

https://www.karger.com/Article/FullText/506196

Similar Items